Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy

Lisa Steinhelfer, Friederike Jungmann, Lukas Endrös, Patrick Wenzel, Bernhard Haller, Manuel Nickel, Eva Haneder, Fabian Geisler, Katharina S. Götze, Alexander von Werder, Matthias Eiber, Marcus R. Makowski, Rickmer Braren, Fabian LohöferJournal of Nuclear Medicine 2024 · DOI

Abstract

Purpose: $^{177}$Lu-DOTATATE therapy is an effective treatment for advanced neuroendocrine tumors (NETs), despite its dose-limiting hematotoxicity. The significance of off-target splenic irradiation remains largely unknown. This study aims to identify predictive markers of peptide receptor radionuclide therapy (PRRT)-induced leukopenia. Methods: We retrospectively analyzed blood counts and imaging data of 88 patients with histologically confirmed, unresectable metastatic NETs treated with $^{177}$Lu-DOTATATE. Automated deep-learning-based segmentation was used to calculate spleen volumes from routine imaging. Results: Absolute and relative white blood cell (WBC) counts and relative spleen volume reduction were independent predictors of radiation-induced leukopenia at 24 months. A 30% decline in spleen volume 12 months after treatment most accurately predicted leukopenia at 24 months (AUC 0.91, sensitivity 0.93, specificity 0.90), significantly outperforming baseline blood counts. Conclusion: Automated splenic volume assessment is a valuable, quantitative imaging-based biomarker for predicting radiation-induced leukopenia, offering potential for improved clinical risk assessment.

Introduction

Peptide Receptor Radionuclide Therapy (PRRT), specifically using $^{177}$Lu-DOTATATE, has revolutionized the treatment of advanced neuroendocrine tumors. However, the therapy's efficacy is often constrained by off-target radiation to healthy tissues, most notably the kidneys and bone marrow. Hematotoxicity, resulting in leukopenia (low white blood cell count), is a major dose-limiting side effect.

Currently, clinicians rely on baseline blood counts to estimate risk, but these metrics often fail to identify patients who will develop late-onset toxicity. Because the spleen expresses high levels of somatostatin receptor subtype 2A (SSTR2A), it accumulates significant radiation during PRRT. This study investigates whether the resulting splenic volume reduction can serve as a "canary in the coal mine" for the broader hematopoietic system.

Methods and Materials

The researchers conducted a retrospective study of 88 patients with metastatic NETs treated between 2009 and 2021 at the Technical University of Munich. Inclusion required at least 24 months of follow-up and a minimum of four treatment cycles. Patients receiving blood transfusions or additional therapies during follow-up were excluded to isolate the effects of PRRT.

Automated spleen segmentation on CT scans.

To ensure objective and efficient measurement, the team employed TotalSegmentator, an open-source deep-learning model, to automatically segment and calculate spleen volumes from routine CT and MRI scans. These volumetric changes at 12 months were then correlated with hematological parameters at 12 and 24 months.

Results

The study revealed a strong and statistically significant correlation between early spleen shrinkage and late-onset white blood cell decline. Approximately 33% of the cohort developed leukopenia by the 24-month mark. Patients who developed leukopenia exhibited an average spleen volume reduction of 36%, compared to only 19% in those who maintained normal blood counts.

Waterfall plot showing the relationship between spleen volume decline and leukopenia.

Key findings include:

  • The 30% Threshold: A 30% decline in spleen volume at 12 months was identified as the optimal predictor for leukopenia at 24 months.
  • Superior Accuracy: This imaging biomarker achieved an Area Under the Curve (AUC) of 0.91, far exceeding the 0.68 AUC achieved by baseline WBC counts.
  • Predictive Power: The 30% cutoff demonstrated a sensitivity of 0.93 and a specificity of 0.90.

Discussion and Conclusion

Splenic contraction likely reflects lymphoid depletion and fibrosis caused by targeted radiation. This volume reduction acts as a measurable proxy for the total radiation burden on the immune system. Unlike static baseline blood tests, automated volumetry captures the dynamic physiological response to ongoing therapy.

While this retrospective, single-center study requires prospective validation, the results suggest that automated splenic volumetry could be seamlessly integrated into clinical workflows. By identifying high-risk patients early, clinicians may be able to adjust treatment intervals or initiate protective measures before severe hematotoxicity occurs. Ultimately, spleen volume reduction represents a robust, routinely available, and highly accurate biomarker for managing long-term toxicity in PRRT.

Summary updated

Abstract

<sup>177</sup>Lu-DOTATATE therapy is an effective treatment for advanced neuroendocrine tumors, despite its dose-limiting hematotoxicity. Herein, the significance of off-target splenic irradiation is unknown. Our study aims to identify predictive markers of peptide receptor radionuclide therapy-induced leukopenia. <b>Methods:</b> We retrospectively analyzed blood counts and imaging data of 88 patients with histologically confirmed, unresectable metastatic neuroendocrine tumors who received <sup>177</sup>Lu-DOTATATE treatment at our institution from February 2009 to July 2021. Inclusion criterium was a tumor uptake equivalent to or greater than that in the liver on baseline receptor imaging. We excluded patients with less than 24 mo of follow-up and those patients who received fewer than 4 treatment cycles, additional therapies, or blood transfusions during follow-up. <b>Results:</b> Our study revealed absolute and relative white blood cell counts and relative spleen volume reduction as independent predictors of radiation-induced leukopenia at 24 mo. However, a 30% decline in spleen volume 12 mo after treatment most accurately predicted patients proceeding to leukopenia at 24 mo (receiver operating characteristic area under the curve of 0.91, sensitivity of 0.93, and specificity of 0.90), outperforming all other parameters by far. <b>Conclusion:</b> Automated splenic volume assessments demonstrated superior predictive capabilities for the development of leukopenia in patients undergoing <sup>177</sup>Lu-DOTATATE treatment compared with conventional laboratory parameters. The reduction in spleen size proves to be a valuable, routinely available, and quantitative imaging-based biomarker for predicting radiation-induced leukopenia. This suggests potential clinical applications for risk assessment and management.
BibTeX
@article{steinhelfer2024spleen,
  author = {Lisa Steinhelfer and Friederike Jungmann and Lukas Endrös and Patrick Wenzel and Bernhard Haller and Manuel Nickel and Eva Haneder and Fabian Geisler and Katharina S. Götze and Alexander von Werder and Matthias Eiber and Marcus R. Makowski and Rickmer Braren and Fabian Lohöfer},
  title = {{Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy}},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.123.267098},
}
Figure